# SURVIVE HERoes (NCT06643585)

> A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06643585
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Prof. Wolfgang Janni
- Conditions: Breast Cancer
- Interventions: Trastuzumab-Deruxtecan; Physicians Choice (PhC).
- Enrollment: 180
- Primary outcome: ctDNA clearance rate 12 months after randomization

## Commentary we found

- YouTube: 3
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=survive-heroes-nct06643585